Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

Y0000443

Flunixin meglumine

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

2-[[2-Methyl-3-(trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic acid meglumine salt, Banamine

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C14H11F3N2O2·C7H17NO5
Numéro CAS:
42461-84-7
Poids moléculaire :
491.46
Numéro MDL:
MFCD01725419
Code UNSPSC :
41116107
ID de substance PubChem :
329830960
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

flunixin

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.Cc1c(Nc2ncccc2C(O)=O)cccc1C(F)(F)F

InChI

1S/C14H11F3N2O2.C7H17NO5/c1-8-10(14(15,16)17)5-2-6-11(8)19-12-9(13(20)21)4-3-7-18-12;1-8-2-4(10)6(12)7(13)5(11)3-9/h2-7H,1H3,(H,18,19)(H,20,21);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1

Clé InChI

MGCCHNLNRBULBU-WZTVWXICSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Flunixin meglumine (IC50 = 1 nM) can be used as a drug for animals for the management of intestinal ischaemia, colic, and endotoxemia in horses.

Actions biochimiques/physiologiques

COX1, COX2 and PLA2 inhibitor non-narcotic analgesic, anti-pyretic, anti-inflammatory.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Y0000445

Flunixin impurity C, European Pharmacopoeia (EP) Reference Standard

Y0000444

Flunixin impurity B, European Pharmacopoeia (EP) Reference Standard

1274607

Flunixin meglumine, United States Pharmacopeia (USP) Reference Standard

1274631

Flunixin Related Compound C, United States Pharmacopeia (USP) Reference Standard

1274630

Flunixin Related Compound B, United States Pharmacopeia (USP) Reference Standard

1274629

Flunixin Related Compound A, United States Pharmacopeia (USP) Reference Standard

PHR2305

Flunixin Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2413

Flunixin Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2823

Flunixin Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

Pictogrammes

Exclamation mark
GHS07

Mention d'avertissement

Warning

Mentions de danger

H315,H319,H335

Classification des risques

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Organes cibles

Respiratory system

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

A J Morton et al.
Equine veterinary journal. Supplement, (39)(39), 112-116 (2011-08-04)
The effects of prostaglandins and nonsteroidal anti-inflammatory drugs (NSAIDs) on repair of equine intestinal mucosa are important since most horses with gastrointestinal diseases are routinely treated with NSAIDs, such as flunixin meglumine (FM), and these drugs can be toxic to
J F Marshall et al.
Equine veterinary journal. Supplement, (39)(39), 106-111 (2011-08-04)
Flunixin meglumine is used for treatment of equine colic despite evidence of inhibited recovery of mucosal barrier function following small intestinal ischaemic injury. This study aimed to characterise an alternative treatment (AHI-805) for abdominal pain in the horse. To determine
J Cuervo-Arango et al.
Theriogenology, 77(3), 514-524 (2011-10-01)
The development of hemorrhagic anovulatory follicles (HAF) involves luteinization and hemorrhage of the follicle. This is observed on ultrasound as an increase in the echogenicity of the granulosa layer and formation of echoic particles in the antrum. The inhibition of
Pharmacokinetic interactions of flunixin meglumine and doxycycline in broiler chickens.
F Yang et al.
Journal of veterinary pharmacology and therapeutics, 36(1), 85-88 (2012-02-02)
G Pugliesi et al.
Theriogenology, 78(2), 443-454 (2012-05-15)
The beginning of postluteolysis (progesterone, <1 ng mL(-1)) in heifers was targeted by using 8 h after ultrasonic detection of a 25% decrease in CL area (cm2) and was designated Hour 0. Flunixin meglumine (FM; n=10) to inhibit PGF2α secretion
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique